These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

748 related items for PubMed ID: 14532785

  • 1. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ, Marion C, Fuks Z, Leibel SA.
    J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
    [Abstract] [Full Text] [Related]

  • 2. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation.
    Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL.
    J Urol; 2002 Aug; 168(2):536-41. PubMed ID: 12131304
    [Abstract] [Full Text] [Related]

  • 3. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [Abstract] [Full Text] [Related]

  • 4. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 5. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
    Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, Vicini FA.
    J Urol; 2003 Mar 01; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
    Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H.
    J Urol; 2006 Oct 01; 176(4 Pt 1):1415-9. PubMed ID: 16952647
    [Abstract] [Full Text] [Related]

  • 11. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA, Kestin LL, Martinez AA.
    Tech Urol; 2000 Jun 01; 6(2):135-45. PubMed ID: 10798815
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
    Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A.
    Int J Radiat Oncol Biol Phys; 2008 Jul 15; 71(4):1028-33. PubMed ID: 18280056
    [Abstract] [Full Text] [Related]

  • 14. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):684-90. PubMed ID: 15183471
    [Abstract] [Full Text] [Related]

  • 15. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S.
    J Clin Oncol; 2005 Sep 20; 23(27):6561-8. PubMed ID: 16170164
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

  • 18. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
    Ryan CJ, Zelefsky MJ, Heller G, Regan K, Leibel SA, Scher HI, Kelly WK.
    Urology; 2004 Jul 15; 64(1):90-4. PubMed ID: 15245942
    [Abstract] [Full Text] [Related]

  • 19. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.
    Urology; 2004 Oct 15; 64(4):754-9. PubMed ID: 15491715
    [Abstract] [Full Text] [Related]

  • 20. Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.
    Igdem S, Abacioglu U, Cetin I, Alco G, Akgun Z, Sengoz M, Bekiroglu N, Turkan S, Okkan S.
    J BUON; 2009 Oct 15; 14(4):629-34. PubMed ID: 20148454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.